Laboratorio Farmaceutico SIT (“SIT”) announces the acquisition of the pharmaceutical product DERINOX from Therabel Lucien Pharma Sas, a reference medicine among topical decongestants. The product is indicated for the short-term symptomatic local treatment of congestive and inflammatory conditions during acute rhinitis, in adults and adolescents over 15 years of age. This acquisition will enable SIT to strengthen and expand its product portfolio, further consolidating its growth path and presence in the French market, establishing itself as a reliable partner in international acquisitions of mature branded pharmaceuticals. SIT continues along its path of innovation and development, reinforcing its offering and international presence to meet the needs of patients and healthcare professionals with high-quality and reliable solutions. The M&A and Life Sciences team of De Berti Jacchia assisted SIT on all legal aspects of the transaction. The team was coordinated by Partner Pietro Meda, with the collaboration of Partner Claudio Corba Colombo and the support of Senior Associates Benedetta Mazzotti and Francesca Zironi. Intellectual property aspects were handled by Partner Andrea Terragni, assisted by Senior Associate Laura Bussoli. Banking aspects were overseen by Partner Giuseppe Cristiano. Download the press review.

With a team led by Partner Pietro Meda, the firm assisted SIT in all phases of the transaction.